These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12100090)

  • 21. A Phase I, Open-Label, Single-Dose Safety, Pharmacokinetic, and Tolerability Study of the Sumatriptan Iontophoretic Transdermal System in Adolescent Migraine Patients.
    Gutman D; Hellriegel E; Aycardi E; Bigal ME; Kunta J; Chitra R; Kansagra S; Kidron OS; Knebel H; Linder S; Ma Y; Pierce M; Winner PK; Spiegelstein O
    Headache; 2016 Sep; 56(8):1300-9. PubMed ID: 27474357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device.
    Luthringer R; Djupesland PG; Sheldrake CD; Flint A; Boeijinga P; Danjou P; Demazières A; Hewson G
    J Pharm Pharmacol; 2009 Sep; 61(9):1219-28. PubMed ID: 19703372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of allergic rhinitis and its treatment on the pharmacokinetics of nasally administered fentanyl.
    Perelman M; Fisher AN; Smith A; Knight A
    Int J Clin Pharmacol Ther; 2013 May; 51(5):349-56. PubMed ID: 23458227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The pharmacokinetics of butorphanol and its metabolites at steady state following nasal administration in humans.
    Vachharajani NN; Shyu WC; Greene DS; Barbhaiya RH
    Biopharm Drug Dispos; 1997 Apr; 18(3):191-202. PubMed ID: 9113342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics, bioequivalence, and spray weight reproducibility of intranasal butorphanol after administration with 2 different nasal spray pumps.
    Wermeling DP; Miller JL; Archer SM; Rayens MK; Rudy AC
    J Clin Pharmacol; 2005 Aug; 45(8):969-73. PubMed ID: 16027409
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration.
    Duquesnoy C; Mamet JP; Sumner D; Fuseau E
    Eur J Pharm Sci; 1998 Apr; 6(2):99-104. PubMed ID: 9795022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human isolated coronary artery contraction to sumatriptan: a post hoc analysis.
    Maassen VanDenBrink A; Bax WA; Ramrattan NN; Ferrari MD; Saxena PR
    Cephalalgia; 1999 Sep; 19(7):651-4. PubMed ID: 10524658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of sumatriptan nasal spray in children.
    Christensen ML; Mottern RK; Jabbour JT; Fuseau E
    J Clin Pharmacol; 2004 Apr; 44(4):359-67. PubMed ID: 15051742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of sumatriptan nasal spray in adolescents.
    Christensen ML; Mottern RK; Jabbour JT; Fuseau E
    J Clin Pharmacol; 2003 Jul; 43(7):721-6. PubMed ID: 12856385
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic Characterization and Dose Selection of a Novel Sumatriptan Nasal Spray Formulation, DFN-02.
    Pal A; Gautam A; Munjal S
    J Clin Pharmacol; 2017 Nov; 57(11):1472-1478. PubMed ID: 28597922
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of pharmacokinetic interaction between butorphanol nasal spray and cimetidine.
    Shyu WC; Barbhaiya RH
    Br J Clin Pharmacol; 1996 Oct; 42(4):513-7. PubMed ID: 8904627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Open-labeled long-term study of the efficacy, safety, and tolerability of subcutaneous sumatriptan in acute migraine treatment.
    Göbel H; Heinze A; Stolze H; Heinze-Kuhn K; Lindner V
    Cephalalgia; 1999 Sep; 19(7):676-83; discussion 626. PubMed ID: 10524662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Butorphanol (Stadol): a study in problems of current drug information and control.
    Fisher MA; Glass S
    Neurology; 1997 May; 48(5):1156-60. PubMed ID: 9153436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sumatriptan and naratriptan tolerability and safety: an update of post-marketing experience.
    Welch KM
    Cephalalgia; 2001; 21 Suppl 1():25-8. PubMed ID: 11678818
    [No Abstract]   [Full Text] [Related]  

  • 35. [Sumatriptan nasal spray for the treatment of cluster headache].
    Watanabe M; Oda A
    No To Shinkei; 2005 Jan; 57(1):65-8. PubMed ID: 15782603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: A randomised, placebo-controlled study.
    Djupesland PG; Docekal P;
    Cephalalgia; 2010 Aug; 30(8):933-42. PubMed ID: 20656704
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of butorphanol nasal spray and fiorinal with codeine in the treatment of migraine.
    Goldstein J; Gawel MJ; Winner P; Diamond S; Reich L; Davidson WJ; Sussman NM
    Headache; 1998; 38(7):516-22. PubMed ID: 15613167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A case of physical and psychological dependence on butorphanol.
    Harshe DG; Mate OS; Cholera RM; Kale S
    J Opioid Manag; 2015; 11(2):112-3. PubMed ID: 26035913
    [No Abstract]   [Full Text] [Related]  

  • 39. Pharmacokinetics of butorphanol after intravenous, intramuscular, and oral administration in Hispaniolan Amazon parrots (Amazona ventralis).
    Guzman DS; Flammer K; Paul-Murphy JR; Barker SA; Tully TN
    J Avian Med Surg; 2011 Sep; 25(3):185-91. PubMed ID: 22216718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioavailability of intranasal butorphanol administered from a single-dose sprayer.
    Davis GA; Rudy AIa; Archer SM; Wermeling DP
    Am J Health Syst Pharm; 2005 Jan; 62(1):48-53. PubMed ID: 15658072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.